AARTI DRUGS
|
AARTI DRUGS Last 5 Year Financial Ratios History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 21.36 | 18.42 | 18.65 | 17.96 | 22.14 |
| CEPS(Rs) | 28.70 | 24.53 | 24.26 | 23.40 | 27.54 |
| DPS(Rs) | 2.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Book NAV/Share(Rs) | 169.70 | 149.99 | 139.40 | 128.77 | 111.92 |
| Tax Rate(%) | 7.57 | 20.62 | 27.15 | 25.79 | 24.06 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 12.15 | 12.16 | 12.69 | 11.39 | 13.36 |
| EBIT Margin(%) | 9.64 | 10.51 | 10.81 | 9.62 | 11.81 |
| Pre Tax Margin(%) | 8.22 | 8.87 | 9.31 | 8.25 | 10.85 |
| PAT Margin (%) | 7.60 | 7.04 | 6.79 | 6.12 | 8.24 |
| Cash Profit Margin (%) | 10.21 | 9.38 | 8.82 | 7.98 | 10.25 |
| Performance Ratios | |||||
| ROA(%) | 7.23 | 6.71 | 7.07 | 7.19 | 10.32 |
| ROE(%) | 13.36 | 12.68 | 13.87 | 14.93 | 21.03 |
| ROCE(%) | 12.04 | 13.11 | 15.01 | 15.49 | 20.75 |
| Asset Turnover(x) | 0.95 | 0.95 | 1.04 | 1.17 | 1.25 |
| Sales/Fixed Asset(x) | 1.57 | 1.66 | 1.95 | 2.29 | 2.19 |
| Working Capital/Sales(x) | 4.70 | 4.76 | 4.81 | 5.01 | 5.49 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.64 | 0.60 | 0.51 | 0.44 | 0.46 |
| Receivable days | 112.48 | 111.30 | 113.27 | 108.50 | 95.71 |
| Inventory Days | 68.56 | 73.31 | 72.33 | 70.03 | 69.00 |
| Payable days | 105.73 | 104.72 | 102.98 | 95.49 | 90.28 |
| Valuation Parameters | |||||
| PER(x) | 14.96 | 18.44 | 23.27 | 18.81 | 19.37 |
| PCE(x) | 11.13 | 13.85 | 17.88 | 14.44 | 15.58 |
| Price/Book(x) | 1.88 | 2.27 | 3.11 | 2.62 | 3.83 |
| Yield(%) | 0.63 | 0.29 | 0.23 | 0.30 | 0.23 |
| EV/Net Sales(x) | 1.36 | 1.55 | 1.80 | 1.37 | 1.80 |
| EV/Core EBITDA(x) | 11.08 | 12.09 | 13.98 | 11.95 | 13.05 |
| EV/EBIT(x) | 14.08 | 14.78 | 16.61 | 14.26 | 15.27 |
| EV/CE(x) | 1.64 | 1.87 | 2.46 | 2.07 | 2.85 |
| M Cap / Sales | 1.14 | 1.30 | 1.58 | 1.15 | 1.60 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 7.47 | -5.60 | -6.90 | 9.14 | 15.49 |
| Core EBITDA Growth(%) | 2.47 | -5.63 | 4.24 | -9.38 | -22.70 |
| EBIT Growth(%) | -1.44 | -8.27 | 4.63 | -11.07 | -25.65 |
| PAT Growth(%) | 15.97 | -2.04 | 3.15 | -18.85 | -26.89 |
| EPS Growth(%) | 15.91 | -1.19 | 3.82 | -18.89 | -26.41 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.37 | 0.45 | 0.44 | 0.51 | 0.52 |
| Current Ratio(x) | 1.59 | 1.60 | 1.66 | 1.57 | 1.48 |
| Quick Ratio(x) | 1.06 | 1.03 | 1.05 | 1.03 | 0.92 |
| Interest Cover(x) | 6.81 | 6.42 | 7.22 | 7.04 | 12.29 |
| Total Debt/Mcap(x) | 0.20 | 0.20 | 0.14 | 0.19 | 0.14 |
Compare Financial Ratios of peers of AARTI DRUGS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| AARTI DRUGS | ₹3,466.7 Cr | -5.7% | -12.2% | -27.5% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹418,204.0 Cr | -1% | -5.5% | 5.7% | Stock Analytics | |
| DIVIS LABORATORIES | ₹240,780.0 Cr | -2.6% | -3.9% | 38.2% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹173,828.0 Cr | -1.7% | -10.2% | 30.5% | Stock Analytics | |
| CIPLA | ₹109,305.0 Cr | 0.9% | -3.2% | -15.2% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹108,759.0 Cr | -0.6% | 1% | -0.1% | Stock Analytics | |
AARTI DRUGS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| AARTI DRUGS | -5.7% |
-12.2% |
-27.5% |
| SENSEX | -1.5% |
-1.2% |
-11.8% |
You may also like the below Video Courses
